Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Highly Probable UK Approval of DCVax-L in 3Q, 2024 Would Be a Crowning Achievement for Northwest Biotherapeutics

Key Points:

On December 21, 2023, NWBO announced that it had submitted its MAA seeking regulatory approval for DCVax-L in…
Read more…

Presentation of DCVax-L Results from ASCO by Dr. Keyoumers Ashkan

Here is the link to a video from ASCO in which Dr. Keyoumers Ashkan summarized the results of the phase…
Read more…

Northwest Biotherapeutics: Debunking Silly, Fictitious Adam Feuerstein Article Falsely Claiming Phase 3 Trial of DCVax-L in Glioblastoma Multiforme Was a Failure

Introduction

I am really outraged. The long awaited phase 3 results for DCVax-L in newly diagnosed and recurrent glioblastoma multiforme were…
Read more…

Presentation at the New York Academy of Sciences on Final Results of Phase 3 DCVax-L Trial Showing Impressive Efficacy (Part 3) Analyzing Hedge Fund Stock Manipulation Techniques

Introduction

This note describes why I believe that the sharp downward price movement yesterday resulted from stock manipulation by a group…
Read more…

Presentation at the New York Academy of Sciences on Final Results of Phase 3 DCVax-L Trial Showing Impressive Efficacy (Part 1) Debunking Hedge Fund Misinformation

Overview

The much anticipated presentation at the New York Academy of Sciences of final results of the phase 3 trial of…
Read more…

Northwest Biotherapeutics (NWBO, $0.86, Buy) Addressing Key Questions Relating to the Possible Approval and Commercialization of DCVax-L in Glioblastoma Multiforme

Introduction

The catalyst for writing this update was the MHRA certification of Northwest Biotherapeutics’ Sawston, UK plant for GMP production…
Read more…

Northwest Biotherapeutics: FDA Statement Regarding Use of External Controls in Clinical Trials is a Huge Positive

I put out a blog last week alerting subscribers that I am writing an update on Northwest Biotherapeutics. I continue…
Read more…

Could There Have Been Hundreds of Millions or Even More Than a Billion Counterfeit Shares of Northwest Biotherapeutics Created Through Illegal Naked Shorting?

I am often asked how I can hypothesize that there may be such an unbelievably large number of counterfeit shares…
Read more…

Northwest Biotherapeutics Issues Encouraging Update on Manufacturing Capabilities (NWBO, $1.59, Buy)

Introduction

This report addresses three issues:

The capability of the Sawston UK plant to manufacture Northwest Biotherapeutics’ dendritic cell vaccine in…
Read more…

Northwest Biotherapeutics: Waiting for Top Line Data on DCVax-L (NWBO, $1.25 Buy)

There has been frenetic trading in Northwest Biotherapeutics stock as investors await the release of topline data from the DCVax-L…
Read more…

Northwest Biotherapeutics: Reason for Yesterday’s Stock Surge (NWBO, Buy, $1.12)

Overview

Northwest Biotherapeutics stock was on fire yesterday as the price increased 35% to $1.12. The strength appears to be…
Read more…

Northwest Biotherapeutics:  Two Recent Press Releases Indicate that Manufacturing is on Track to Support Commercialization of DCVax-L (NWBO, Buy, $0.55)

Clinical Data Offers Much Hope that Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma Multiforme Will Be Successful

Northwest continues…
Read more…

Northwest Biotherapeutics: (NWBO, Buy, $0.35) Management Issues Guidance That DCVax-L Phase 3 Trial Results Will Be Released Sometime After Labor Day

Investment Overview: Highly Asymmetric Outlook

Northwest Biotherapeutics has guided that it will report results of the phase 3 trial of DCVax-L…
Read more…

Northwest Biotherapeutics: We Are Just Several Weeks from Release of Topline Data in Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma Multiforme (NWBO, $0.36, Buy)

Investment Overview

In the 1Q, 2020; 10-Q regulatory release on June 24, there was a section that went into some detail…
Read more…

Northwest Biotherapeutics (NWBO, Buy, $0.26)  Detailed Results for the Phase 3, DCVax-L Trial in ndGBM Are Imminent

Introduction

Results for the phase 3 trial of DCVax-L in the treatment of newly diagnosed glioblastoma multiforme (ndGBM) should be released…
Read more…

Northwest Biotherapeutics: Why I Believe there is a High Probability for Approval of DCVax-L (NWBO, Buy, $0.21)

Investment Overview

There are Good Reasons to Believe that Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma Multiforme Will Be…
Read more…

Novocure: First Report on this Dynamic Growth Stock with Important Similarities to Northwest Biotherapeutics (NVCR, $78.77)

Investment Overview

My reason for first looking at Novocure in depth was that it provided important comparative information versus Northwest Biotherapeutics’…
Read more…

Northwest Biotherapeutics: Management’s Decision to Determine Survival Tail for DCVax-L in Phase 3 Trial in Newly Diagnosed Glioblastoma Was Absolutely the Right Move (NWBO, Buy, $0.25)

Key Points:

NWBO is approaching unblinding of the critical phase 3 trial of DCVax-L in newly diagnosed glioblastoma (GBM).
Management…
Read more…

Northwest Biotherapeutics: Takeaways from Marnix Bosch’s Presentation at ASCO (NWBO, Buy, $0.27)

Overview

Marnix Bosch, Chief Technical Officer of Northwest Biotherapeutics, discussed three broad topics at ASCO on Sunday June 2, 2019.

Factors…
Read more…

Northwest Biotherapeutics: Non-Dilutive Financing Provides Major Boost to Investment Outlook (NWBO, $0.25, Buy)

Key
Points:

Monetization of a UK manufacturing facility has brought in roughly $46 million of non-dilutive cash.I estimate that payment of debt…
Read more…

Northwest Biotherapeutics: Blinded Data from DCVax®-L Phase 3 Trial is Extremely Encouraging, But We Still Need to See Unblinded Data (NWBO, Buy, $0.29)

Overview

This report starts with a summary of the key aspects of my investment thinking on Northwest,updated for the just reported…
Read more…

Northwest Biotherapeutics: There could be Overwhelming Patient Demand for DCVax-L due to the Right to Try law (NWBO, $0.24, Buy)

Investment Thesis in Brief

I believe that it is now a matter of when rather than if DCVax-L is approved and…
Read more…

Northwest Biotherapeutics; Five Spectacular Patient Outcomes for Patients Treated with DCVax-L as Reported at ASCO (NWBO, $0.28, Buy)

Purpose of Report:

At ASCO, Northwest sponsored a meeting attended by investigators in the phase 3 trial and other oncologists not…
Read more…

Northwest Biotherapeutics: Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L (NWBO, Buy, $0.30)

Investment Perspective

Last week, a manuscript was published in a peer reviewed journal that dealt with blinded results of the phase…
Read more…

Northwest Biotherapeutics: How the Right to Try Remarks in President Trump State of the Union Could Favorably Affect Regulatory Action on DCVax-L and DCVax Direct (NWBO, Buy, $0.33)

Introduction

This report deals with comments made by President Trump in the State of the Union address in which he indicated…
Read more…

Northwest Biotherapeutics: Thoughts on Why the Phase 3 Trial of DCVax-L is Ongoing (NWBO, BUY, $0.17)

Overview

The phase 3 trial of DCVax-L in newly diagnosed glioblastoma is continuing even though it has passed the 248 PFS…
Read more…

Northwest Biotherapeutics, Bristol-Myers Squibb: Success for the Yervoy-Opdivo Combination in CHECKMATE-214 Trial Obviously is a Major Positive for BMY, but also has Important Implications for NWBO (NWBO, Buy, $0.19) (BMY, $60.80, Buy)

The stoppage at an interim analysis of Bristol-Myers Squibb’s’ CHECKMATE-214 trial provides meaningful information into assessing the potential fro success…
Read more…

Northwest Biotehrpeutics: How Does DCVax-L Clinical Data Compare to the CAR-T Therapy Axi-Cel? (NWBO, $0.18, Buy)

New Seeking Alpha Article on Seeking Alpha

An article on Seeking Alpha called Northwest Biotherapeutics: Statistically Satisfying was just published by…
Read more…

Northwest Biotherapeutics: Why I Believe That the Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma Patients Has a Very Good Chance for Success (NWBO, Buy, $0.17)

Overview

This report is an extensive update on almost everything I know about the DCVax-L phase 3 trial and is over…
Read more…

Northwest Biotheraputics to Make Presentation at ASCO Today Monday June 5, 2017

Northwest issued a press release announcing a presentation at ASCO today by the Company’s Chief Technical Officer, Dr. Marnix Bosch.…
Read more…

Northwest Biotherapeutics: Is There Any Chance for DCVax-L to be Successful in the Phase 3 Trial? (NWBO, Buy, $0.24)

Acronyms Used in this Report

SOC: The standard of care in newly diagnosed glioblastoma patients is surgical resection followed by…
Read more…

Northwest Biotherapeutics and Agenus: What Are The Implications for These Companies in the Aftermath of Two Recent Cancer Vaccine Trial Failures? (NWBO, $0.38, Buy) (AGEN, $3.99, Buy)

Two Recent Cancer Vaccine Trial Failures Spurred this Report

On February 22, 2017, Argos reported that the Data Monitoring Committee for…
Read more…

Northwest Biotherapeutics: 8-K Document Released Today Provides New and Very Interesting Data on Patients Treated with DCVax-L. (NWBO, Buy, $0.48)

Substance of 8-K Regulatory Document

Northwest issued an 8-K today in response to shareholders’ questions about an issue that has been…
Read more…

Northwest Biotherapeutics: Partial Clinical Hold on Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma is Lifted (NWBO, Buy, $0.45)

Key Points:

Lifting of the partial hold removes a cloud that has been overhanging the Company for the past 18…
Read more…

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Purpose of this Report

I last summarized my stock recommendations in a September 12, 2016 report. There has been little change…
Read more…

Northwest Biotherapeutics: DCVax-L Viewed Through the Eyes of Dr. Linda Liau, Lead Investigator on the Phase 3 Trial of DCVax-L (NWBO, $0.35, Buy)

Principal Takeaway Messages  from This Report

Dr. Linda Liau believes that use of DCVax-L can result in 25% of glioblastoma patients…
Read more…

Northwest Biotherapeutics: Phase 2 Trial in Colorectal Cancer with Liver Metastases Announced (NWBO, Buy, $0.55)

NWBO is preparing for the start of a phase 2 trial combining DCVax-L with Merck’s Keytruda in late stage colorectal cancer with…
Read more…

Northwest Biotherapeutics: Recent Data Update on Phase 1/2 Trial of DCVax Direct is Encouraging (NWBO, Speculative Buy, $0.43)

Key Points:

Data for DCVax Direct recently was updated for its phase 1/2 trial in 40 patients having 13 different…
Read more…

Northwest Biotherapeutics: Going Over My Thoughts (NWBO, $0.62)

Overview

The naming of five distinguished scientists with extensive knowledge and expertise in immune-oncology to Northwest’s scientific advisory board is the…
Read more…

Northwest Biotherapeutics: The Company Provides an Operations Update (NWBO, $1.23)

Report Overview

I usually start my reports with a summary and investment thesis. However, in this report I am putting this…
Read more…

Northwest Biotherapeutics: A Comprehensive Evaluation of Its Lead Product DCVax-L (NWBO, $1.50)

Perspective and Overview on this Report

The still unexplained and unresolved halt in screening for the phase 3 trial of DCVax-L…
Read more…

Northwest Biotherapeutics: Why the Failure of Celldex’s Rintega in Newly Diagnosed Glioblastoma Probably Has No Implications for the DCVax-L Trial

Investment Thesis

Some subscribers have asked me if the failure of Rintega in the phase 3 ACT-IV trial in newly diagnosed…
Read more…

Northwest Biotherapeutics: Seeking Alpha Publishes Latest in a String of Attack Articles Authored by Short Sellers (NWBO, $4.92)

Seeking Alpha has published an extremely negative article by anonymous short sellers that alleges criminal misconduct on the part of management…
Read more…

Northwest Biotherapeutics: New Financing from Woodford was Much Needed (NWBO, $5.44)

Curses, Foiled Again; The Hedge Fund’s Lament

The clear intent of the recent short attack on Northwest was at a minimum…
Read more…

Northwest: Analysis of a Coordinated Short Selling Attack Against the Stock (NWBO, $4.69)

A Suspect Plunge in Price

On Friday October 16, 2015 a day in which the Dow Jones and S&P averages increased…
Read more…

Northwest Biotherapeutics: My Thoughts on the New Data from the Phase 1/2 Trial of DCVax Direct (NWBO, Buy, $6.91)

Critical Issue in Interpreting the Data
Northwest just recently presented length of survival data for 39 patients evaluated in its phase…
Read more…

Northwest Biotherapeutics: Thoughts on Suspension of Screening of New Patients in the Phase 3 DCVax-L Trial

Reason for Report

On August 21, Northwest put out a press release that said that screening of new patients has been…
Read more…

Comments on Agenus, ImmunoCellular, Discovery Laboratories, Neuralstem, Kite and Juno

SmithOnStocks Mailbox
 Comments on Agenus, ImmunoCellular, Discovery Laboratories, Neuralstem, Kite and Juno
About the Mailbox:

My mailbox comments are brief notes on stocks…
Read more…

Implication of the Juno Celgene Deal for Emerging Immuno-Oncology Biotechnology Stocks in General and Northwest Biotherapeutics in Particular

The Terms of the Juno Celgene Deal

Celgene and Juno announced a ten year collaboration for drug development using CAR-T therapy…
Read more…

Observations from ASCO on Immuno-oncology with a Focus on Northwest Biotherapeutics’ (NWBO, Buy, $9.43) DC-Vax-Direct© and the Checkpoint Inhibitors of Bristol-Myers Squibb and Merck

Key Investment Points Stemming from ASCO

I have been going over data presented at ASCO on immune-oncology products and have been…
Read more…

Comments on Antares, Kite Pharma and Northwest Biotherapeutics

SmithOnStocks Mailbox
About the Mailbox:

My mailbox comments are brief articles on stocks in which I am involved. These can come from…
Read more…

CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?

Introduction to This Thought Piece

Emerging biotechnology stocks obviously are very hard to value on an absolute basis because they usually…
Read more…

Northwest Biotherapeutics: Comments on Two AACR Posters (NWBO, $8.62, Buy)

Introduction

I have included an abstract on DCVax Direct and another on DCVax-L that will be presented in poster presentations at…
Read more…

Northwest Biotherapeutics: The $40 Million Woodford Financing is A Major Positive (NWBO, Buy, $7.76)

The $40 million will fund the Company through the end of 2015.
CEO Linda Powers indicates that this is the cornerstone…
Read more…

Northwest Biotherapeutics: Still Another Rebuttal to a Feuerstein Attack Is Called For

Introduction

Adam Feuerstein just published a blog that attacks the results and conclusions drawn from the paper summarizing results from the…
Read more…

Northwest Biotherapeutics: Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Multiforme (NWBO, Buy)

Executive Summary
Northwest Biotherapeutics has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically…
Read more…

Northwest Biotherapeutics: Highlights of the 2014 10-K (NWBO, Buy, $7.81)

Introduction

Northwest Biotherapeutics just issued their 10-K for 2014 and I would urge everyone to read it. The purpose of this…
Read more…

Northwest Biotherapeutics: How Much Will It Cost to Manufacture DCVax-L (NWBO, Buy, $7.26)

There has been a lot of speculation about how much it costs to manufacture one course of individualized therapy of…
Read more…

The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology Landscape (NWBO, Buy, $6.19)

Investment Overview

Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential…
Read more…

Northwest Biotherapeutics: Some Thoughts about the Upcoming Presentation by CEO Linda Powers on Monday, January 26th. (NWBO, Buy, $6.28)

Ms. Powers will present at 10:30 AM.
She will then participate in a discussion panel with representatives from Amgen, Roche Diagnostics,…
Read more…

Notes from Linda Powers Presentation in San Francisco, January 12, 2015 (NWBO, Buy, $6.00)

Overview

Linda Powers spoke at the Biotech Showcase Conference in San Francisco on January 12, 2015. My Buy recommendation on Northwest Biotherapeutics…
Read more…

Northwest Biotherapeutics: Putting Recent Clinical Data on DCVax Direct in Perspective (NWBO, Buy, $5.37)

Immuno-oncology is one of the most exciting areas for cancer research and cancer vaccines should be considered as a promising…
Read more…

My Dialogue with Adam Feuerstein on Northwest Biotherapeutics

Perspective
I think that all investors in Northwest Biotherapeutics (NWBO) would concur that Adam Feuerstein has a vendetta against NWBO and…
Read more…

Northwest Biotherapeutics: Exciting News on Potential for Early Patient Access for DCVax-L in the UK

UK designates DCVax-L as first drug to be considered for early access approval under recently enacted EAMS program.
Earlier this year,…
Read more…

Northwest Biotherapeutics: National Geographic Special Features DCVax Direct Treatment of Stage 4 Pancreatic Cancer Patient (NWBO, Buy, $5.90)

DCVax Direct was used in a patient with stage 4 pancreatic cancer whose chemotherapy was stopped.
The patient, a Nat Geo…
Read more…

Northwest Biotherapeutics: Independent Chairman of the DMC Committee for DCVax-L Phase 3 Trial Chastises Adam Feuerstein for Inaccurate Articles (NWBO, Buy, $6.43)

 

The Data Monitoring Committee (DMC) is charged with monitoring the safety and efficacy results of clinical trial. The committee and…
Read more…

CREW Alleges That Adam Feuerstein is Involved in Stock Manipulation Scheme in Regard to Northwest Biotherapeutics

Citizens for Responsibility and Ethics in Washington (CREW) have gone after Adam Feuerstein of The Street.com. They have accused him…
Read more…

Northwest Biotherapeutics: Market Research Firm Evaluate Pharma Projects 2020 Worldwide Sales of $2.0 billion for DCVax-L (NWBO, Buy, $5.92)

One of the basic charges made against me by Richard Pearson and other short sellers is that they maintain that…
Read more…

Northwest Biotherapeutics: Sixteenth Feuerstein Attack on the Company (NWBO, Buy, $8.11)

Adam Feuerstein has just  launched its 16th negative blog on Northwest Biotherapeutics since the beginning of March and this has…
Read more…

Northwest Biotherapeutics: The Perfect Storm May Be Brewing for Short Sellers (NWBO, $7.66, Buy, Free Content)

I wrote on June 12th  that NWBO stockholders may be seeing a changing in the tide of investor opinion. The…
Read more…

Northwest Biotherapeutics: The Investment Tide May be Turning Positive (NWBO, Buy, $6.41, free content)

Purpose of Report

This report goes over recent news on the company in regard to DCVax Direct and DCVax-L and then…
Read more…

Northwest Biotherapeutics to Host Conference Call This Afternoon, May 27th (NWBO, Buy, $6.25)

Northwest Biotherapeutics announced today that the Company will host a conference call and webcast  with CEO Linda Powers today, May…
Read more…

Northwest Biotherapeutics: Update On DCVax-Direct Based on ASCO Abstract and Positive, Early Results for First Patient Reported On (NWBO, Buy, and $5.94)

Investment Conclusion

The ASCO abstract on DCVax-Direct was released last night. It contains only a description of the drug and the…
Read more…

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

Northwest Biotherapeutics: Just Announced Financing Signals High Expectations for Use of DCVax-L under German Hospital Exemption Program (NWBO, $6.75, Paid Subscribers)

Purpose of New Financing

Northwest Biotherapeutics just announced a financing in which a single institutional investor bought $15 million of stock…
Read more…

Refuting Feuerstein’s Latest Negative Blog on Northwest Biotherapeutics (NWBO, Buy, $7.56)

Before I Get Into This Article, a Word to My Subscribers

I want to apologize to my subscribers for a software…
Read more…

Northwest Biotherapeutics (NWBO, Buy, $7.59) What the 2014 10-K Had to Say about the Approval of DCVax-L under the German Early Access Program

Purpose of This Blog

The approval of DCVax-L under the hospital exemption early access program was a stunning positive in my…
Read more…

Linda Powers, CEO of Northwest Biotherapeutics, Attacks and Debunks the Weak Bear Case in a Presentation on March 27

Overview

Northwest Biotherapeutics CEO Linda Powers made a presentation yesterday in which she addressed the bear case that has resulted in…
Read more…

SmithOnStocks Mailbox February 25, 2014

I have found that there are some very smart people out there who have interesting questions and perspectives concerning my…
Read more…

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

Back From BIO CEO Conference

I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria…
Read more…

SmithOnStocks Mailbox January 28, 2014

In my writing, I have found that there are some very smart people out there who have interesting questions and…
Read more…

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

What SmithOnStocks Is All About
It is traditional at the start of the year to go over stock picks for the…
Read more…

Adam Feuerstein’s Views on Northwest Biotherapeutics (NWBO, $3.37)

Adam Feuerstein has consistently disagreed with authors who believe that there is a sound basis for Northwest Biotherapeutics (NWBO) conducting…
Read more…

Northwest Biotherapeutics: An Analysis of Its Transforming Balance Sheet Restructuring (NWBO, $4.14)

Key Takeaway Points of this Report
Northwest (NWBO) restructured much of its debt in 4Q, 2012 and also has raised significant…
Read more…

Northwest Biotherapeutics ($3.44): M.D. Anderson’s Lead Role in DCVax Direct Trial is Encouraging

Northwest Biotherapeutics (NWBO) announced today that the phase I/II trial of DCVax Direct has been initiated at M.D. Anderson Cancer…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, June 2, 2013

Overview of This Week's Report
This week I published a major report on Alimera Sciences and pSivida which led to my…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, May 28, 2013

Introduction
I have started to write a newsletter on a weekly or bi-weekly basis to supplement my reports and blogs. In…
Read more…

Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward and Starting DC Vax Direct Trials (NWBO, $3.63)

Investment Thesis
This report is an update based on a number of recent events. I discuss encouraging long term survival results…
Read more…

Northwest Biotherapeutics: My Rationale for Having a Buy Recommendation (NWBO; $3.29)

Crossing Swords
Adam Feuerstein of The Street.com and I crossed swords after I wrote an article in response to a very…
Read more…

Northwest Biotherapeutics: A Critique of Adam Feuerstein of TheStreet's Recent Analysis (NWBO, $3.50)

Purpose of this Report
I have undertaken a point by point examination of a negative blog on Northwest Biotherapeutics (NWBO) by…
Read more…

Northwest Biotherapeutics: Transformed from an Ugly Duckling Bulletin Board Company to a Promising NASDAQ Company (NWBO, $3.20)

Investment Update
In my July 19, 2012 report Northwest Biotherapeutics' DCVax Cancer Vaccines May Be a Game Changer in Cancer Therapy,…
Read more…

Northwest Biotherapeutics Stock Surges 94% on Perfect Storm Created by Short Squeeze and New Buying Interest (NWBOD, $10.75)

Investment Summary
Northwest Biotherapeutics’ (NWBOD) stock price increased 94% on Friday, September 28 to $10.95 per share and investors are asking…
Read more…

Thoughts on Northwest Biotherapeutics’ Reverse Stock Split

Northwest Biotherapeutics (NWBO.OB) announced a 1 for 16 reverse stock split. This is a first step in a planned public…
Read more…

Northwest Biotherapeutics and ImmunoCellular Therapeutics Can Both Be Winners with their Cancer Vaccines (NWBOD, $5.50)

Investment Perspective
I think that some investors are incorrectly viewing the investment outlook for Northwest Biotherapeutics and ImmunoCellular Technologies (IMUC.OB). Both…
Read more…

Manish Singh Resigns as CEO of ImmunoCellular Therapeutics: Implications for Northwest Biotherapeutics and ImmunoCellular

ImmunoCellular (IMUC.OB) has issued a press release stating that Manish Singh has resigned as CEO. He will be succeeded in…
Read more…

Northwest Biotherapeutics' DC Vax Cancer Vaccine May Be a Game Changer In Cancer

 

I am starting my coverage of Northwest Biotherapeutics (NWBO.OB) with a Buy. I became interested in this small bulletin board…
Read more…

Northwest Biotherapeutics’ DCVax Cancer Vaccines May Be a Game Changer In Cancer Therapy (NWBO, $0.22)

Northwest Biotherapeutics' DC Vax Cancer Vaccine May Be a Game Changer
In Cancer Therapy

Report Outline
Investment Thesis and Opinion
Introduction
Phase I Trial…
Read more…

Highlighting A New Report on Dendritic Cell Cancer Vaccines

Northwest Biotherapeutics’ (NWBO) DCVax-L and ImmunoCellular Therapeutics’ ICT-107 are dendritic cell cancer vaccines that are in phase II trials for…
Read more…

The Rationale Behind Dendritic Cell-Based Cancer Vaccines and How They are Manufactured (NWBO.OB, $0.22)

Dendritic Cell-Based Cancer Vaccines Could Be a Major Advance
In October of 2011, Dr. Ralph Steinman was post-humously awarded one-half of…
Read more…